AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Hervycta 440mg Injection

Prescription Icon
Prescription Required

Marketer

Dr Reddy's Laboratories Ltd

Salt Composition

Trastuzumab (440mg)

Overview Hervycta 440mg Injection

Oncaspar 440mg Injection is indicated for treating breast and gastric cancers. Its mechanism involves targeting and eliminating cancerous cells by suppressing HER2, the human epidermal growth factor receptor 2 protein. Administration is strictly via injection by a healthcare professional. Dosage frequency and amount are determined individually by your physician, varying based on your condition and potentially adjusted over time. Always adhere precisely to your doctor's prescribed regimen; improper usage or overdose can result in severe adverse reactions. Therapeutic effects may not be immediately apparent, potentially requiring weeks or months; discontinue use only under medical guidance. Frequently reported side effects include nausea, headache, skin rash, sleep disturbances, and increased infection risk. This medication can lower blood cell counts (both red and white), increasing vulnerability to infections. Regular blood tests are essential to monitor blood cell levels, alongside heart, liver, and uric acid levels. Report any shortness of breath, cough, chills, or limb swelling to your doctor immediately. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners throughout treatment to prevent conception.

Uses of Hervycta 440mg Injection

Malignancies of the breast and stomach

Major Benefits of Hervycta 440mg Injection:

This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.

Common Side effects of Hervycta 440mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Hervycta 440mg Injection:

This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.

How Hervycta 440mg Injection works:

Hervycta 440mg Injection, a recombinant IgG1 monoclonal antibody, targets HER2 (human epidermal growth factor receptor 2), receptors implicated in the uncontrolled growth of breast and gastric cancer cells. Its mechanism involves HER2 inhibition, thereby halting cancer cell proliferation and disrupting downstream signaling cascades associated with oncogenesis.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concomitant use of Hervycta 440mg Injection and alcohol may result in increased somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Hervycta 440mg Injection during pregnancy poses a confirmed risk to the fetus. Its use is contraindicated except in exceptional, life-threatening circumstances where the potential benefits outweigh the known hazards, as determined by a physician. Physician consultation is mandatory.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Using the injection Hervycta 440mg while breastfeeding is likely unsafe. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

Hervycta 440mg Injection's impact on driving ability is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Hervycta 440mg Injection in individuals with kidney disease appears to pose minimal risk. Existing evidence indicates that altering the Hervycta 440mg Injection dosage for such patients may be unnecessary. However, medical advice should be sought.

LiverLiverCONSULT YOUR DOCTOR

Insufficient data exists regarding the administration of Hervycta 440mg Injection to individuals with hepatic impairment. Physician consultation is advised.

What if you forget to take Hervycta 440mg Injection :

Should you forget a dose of Hervycta 440mg Injection, seek medical advice.

Facts to Know About Hervycta 440mg Injection

LabelValue
Chemical Type Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Actions Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Hervycta 440mg Injection

Hervycta 440mg Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bleeding or bruising. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea, vomiting, loss of appetite, rapid heartbeat, urine discoloration, decreased or painful urination, difficulty urinating, and signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Women of childbearing age must use effective contraception throughout Hervycta 440mg Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Treatment with Hervycta 440mg Injection for early breast cancer should last one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Hervycta 440mg Injection does not require fasting beforehand. Administration must be overseen by a physician experienced in cancer chemotherapy and performed only by a qualified healthcare professional.
Hervycta 440mg Injection is available in two formulations: intravenous infusion and subcutaneous injection. Always verify the correct formulation is administered as prescribed, as the intravenous formulation is for intravenous use only. Your doctor may change your treatment between intravenous and subcutaneous Hervycta 440mg Injection if clinically appropriate.
Hervycta 440mg Injection is a monoclonal antibody targeting the HER2 protein, abundant on the surface of some cancer cells. Because it works by binding to HER2 to inhibit cancer growth, it's only effective in patients with HER2-positive cancer and is not indicated for use in HER2-negative patients.
Using Hervycta 440mg Injection with anthracyclines (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and during treatment.
Cardiac evaluations should begin at treatment initiation, continue every three months throughout treatment, and then every six months post-treatment for up to 24 months following the final Hervycta 440mg Injection. Patients with pre-existing cardiac conditions require evaluations every twelve weeks.
Hervycta 440mg Injection
16,289
MRP 18,900
13% off